[go: up one dir, main page]

WO2006006691A3 - Solid dispersion of a p38 map kinase inhibitor - Google Patents

Solid dispersion of a p38 map kinase inhibitor Download PDF

Info

Publication number
WO2006006691A3
WO2006006691A3 PCT/JP2005/013099 JP2005013099W WO2006006691A3 WO 2006006691 A3 WO2006006691 A3 WO 2006006691A3 JP 2005013099 W JP2005013099 W JP 2005013099W WO 2006006691 A3 WO2006006691 A3 WO 2006006691A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid dispersion
kinase inhibitor
map kinase
present
drug release
Prior art date
Application number
PCT/JP2005/013099
Other languages
French (fr)
Other versions
WO2006006691A2 (en
Inventor
Yoshihiro Omachi
Takashi Kurasawa
Original Assignee
Takeda Pharmaceutical
Yoshihiro Omachi
Takashi Kurasawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical, Yoshihiro Omachi, Takashi Kurasawa filed Critical Takeda Pharmaceutical
Publication of WO2006006691A2 publication Critical patent/WO2006006691A2/en
Publication of WO2006006691A3 publication Critical patent/WO2006006691A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a solid dispersion containing (i) a p38 MAP kinase inhibitor, (ii) carrier(s), (iii) plasticizer(s) and (iV) drug release-controlling component(s). According to the present invention, the solubility of poorly soluble or insoluble drugs can be improved and a drug release-controlling function can be provided simultaneously in a single manufacturing process, and a solid dispersion having a uniform composition and permitting sustained- release of drugs can be provided.
PCT/JP2005/013099 2004-07-09 2005-07-08 Solid dispersion of a p38 map kinase inhibitor WO2006006691A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-203799 2004-07-09
JP2004203799A JP2007223903A (en) 2004-07-09 2004-07-09 Novel solid dispersion and its manufacturing method

Publications (2)

Publication Number Publication Date
WO2006006691A2 WO2006006691A2 (en) 2006-01-19
WO2006006691A3 true WO2006006691A3 (en) 2006-03-30

Family

ID=34979219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/013099 WO2006006691A2 (en) 2004-07-09 2005-07-08 Solid dispersion of a p38 map kinase inhibitor

Country Status (3)

Country Link
JP (1) JP2007223903A (en)
TW (1) TW200608996A (en)
WO (1) WO2006006691A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2011102505A1 (en) * 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
WO2011102504A1 (en) 2010-02-22 2011-08-25 第一三共株式会社 Sustained-release solid preparation for oral use
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
JPWO2020261619A1 (en) * 2019-06-26 2020-12-30

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180518A1 (en) * 1999-04-23 2002-02-20 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US20030077322A1 (en) * 2000-05-20 2003-04-24 Lee Sang Deuk Solid dispersion system of pranlukast with improved dissolution and method for preparing the same
US20030181411A1 (en) * 2002-03-20 2003-09-25 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1180518A1 (en) * 1999-04-23 2002-02-20 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US20030077322A1 (en) * 2000-05-20 2003-04-24 Lee Sang Deuk Solid dispersion system of pranlukast with improved dissolution and method for preparing the same
US20030181411A1 (en) * 2002-03-20 2003-09-25 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

Also Published As

Publication number Publication date
WO2006006691A2 (en) 2006-01-19
TW200608996A (en) 2006-03-16
JP2007223903A (en) 2007-09-06

Similar Documents

Publication Publication Date Title
PL1663216T3 (en) Modified release compositions comprising tacrolimus
TNSN06434A1 (en) Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
ATE226066T1 (en) METHOD FOR STABILIZING POLYVINYLPYRROLIDONE PREPARATIONS
WO2007146248A3 (en) Stable laquinimod preparations
AU2003300833A1 (en) Solid compositions with improved bio-availability of insoluble or poorly water soluble drugs and a corresponding process for preparing such
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2000021572A3 (en) Hydrogels and water soluble polymeric carriers for drug delivery
WO2007075972A3 (en) Chlorite formulations, and methods of preparation and use thereof
WO2007146293A3 (en) Improved composition and method for taste masking
UA95253C2 (en) Camptothecin analogue compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds
WO2006006691A3 (en) Solid dispersion of a p38 map kinase inhibitor
ZA200705119B (en) Matrix type sustained-release preparation containing basic drug or salt thereof, and method for manufacturing the same
NO20005838L (en) Pharmaceutical multiparticulate form with programmed and controlled release, as well as manufacture thereof
WO2004069180A3 (en) Solid dispersion compositions
WO2008057704A3 (en) A jewelry item with a novel setting for precious stones
WO2003099228A3 (en) Compositions and processes for inhibiting gene expression using polynucleotides
DK1742927T3 (en) Butanonic acid derivatives, processes for their preparation, pharmaceutical compositions comprising them, and pharmaceutical applications thereof
TW200514576A (en) Diffusion layer modulated solids
WO2002036067A3 (en) Long-acting cytokine derivatives and pharmaceutical compositions comprising them
ES2169980A1 (en) Microcapsules for sustained release of drugs
WO2005077951A3 (en) 7h-pyrrolopyrimidine derivatives
WO2001030372A3 (en) Pharmaceutical agent preparations
WO2005110363A3 (en) Systems and methods for preparation of pharmaceutical dosage using compositions containing aqueous vesicles
ATE318268T1 (en) PYRAZOLYL-SUBSTITUTED TRIAZOLOQUINOXALINES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase